Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04696731
Title Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (TRAVERSE)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Allogene Therapeutics
Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.